Skip to content
HowShorted

Karyopharm Therapeutics Inc. short interest in 2021

In 2021, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 21.55% of shares outstanding on 15 Jan 2021 to 16.05% on 31 Dec 2021, a change of -5.50 percentage points. The year's high was 22.45% on 26 Feb 2021 and its low 16.05% on 31 Dec 2021, averaging 19.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.16 days on 30 Jul 2021. Full history: Karyopharm Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Karyopharm Therapeutics Inc. in 2021

2021 in figures

Start of year
21.55% (15 Jan 2021)
End of year
16.05% (31 Dec 2021)
Change
-5.50 pp
High
22.45% (26 Feb 2021)
Low
16.05% (31 Dec 2021)
Average
19.22%
Highest days to cover
18.16 (30 Jul 2021)
SEC filings marked
9

Every report in 2021

Karyopharm Therapeutics Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202121.55%6.69results (8-K)
29 Jan 202119.28%5.09
12 Feb 202121.39%4.40results (8-K)
26 Feb 202122.45%7.6310-K filed
15 Mar 202120.88%6.89
31 Mar 202120.74%7.99
15 Apr 202121.31%13.86
30 Apr 202119.81%11.10
14 May 202119.79%5.99results (8-K), 10-Q filed
28 May 202118.26%12.55
15 Jun 202119.23%9.90
30 Jun 202120.04%10.40
15 Jul 202120.03%13.90
30 Jul 202119.94%18.16
13 Aug 202118.59%4.8610-Q filed, results (8-K)
31 Aug 202118.45%9.07
15 Sep 202117.47%10.33
30 Sep 202119.12%10.38
15 Oct 202117.68%13.07
29 Oct 202117.36%12.62
15 Nov 202117.13%3.1910-Q filed, results (8-K)
30 Nov 202116.83%7.41
15 Dec 202117.85%6.06
31 Dec 202116.05%5.12

See also: Karyopharm Therapeutics Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.